Folate in preventive medicine: A new role in cardiovascular disease, neural tube defects and cancer

Annals of Nutrition and Metabolism

Volumn 41, Issue 6, 1997, Pages 331-343

  Pietrzik, Klaus ^a   Bronstrup, Anja ^a  

^a UNIVERSITY OF BONN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

FOLIC ACID; HOMOCYSTEINE;

AMINO ACID METABOLISM; BIOCHEMISTRY; CANCER PREVENTION; CARDIOVASCULAR DISEASE; HUMAN; NEURAL TUBE DEFECT; PREVENTIVE MEDICINE; PRIORITY JOURNAL; REVIEW;

EID: 0342762007     PISSN: 02506807     EISSN: 14219697     Source Type: Journal    
DOI: 10.1159/000178004     Document Type: Article

References (87)

1. Carson NAJ. Neill DW: Metabolic abnormalities detected in a survey of mentally backward individuals in Northern Ireland. Arch Dis Child 1962;37:505-513.
2. Kang SS. Wong PWK. Zhou J. Sora J. Lessik M. Ruggie N. Grcevich G; Thermolabile mcthylcnctctrahydro-folatc reductase in patients with coronary artery disease. Metabolism 1988;37:611-613.
3. Put NMJ, van der, Esher TKAB, Blom HJ,: Is the common 677C-> T mutation in the mcthylenctctrahy-drofolate reductase gene a risk factor for neural tube defects? A metaanalysis. Q J Med 1997:90:111-115.
4. Stamler JS. Slivka A: Biological chemistry of thiols in the vasculature and in vascular-related disease. NutrRev 1996;54:1-30.
5. Harpel PC, Chang VT, Borth W,: Homocysteine and other sulfhydryl compounds enhance the binding of lipoprotcin(a) to fibrin: A potential biochemical link between thrombosis, alherogenesis. and sulfhydryl compound metabolism. Proc Nat Acad Sci USA 1992:89:10193-10197.
6. Bellamy MF, Ramsey MW, Brownlee M, McDowell IFW, Lewis MJ,: Hyperhomocysteinaemia and endothelial dysfunction following an oral methionine load in healthy subjects. Pteridines 1997;8:158-159.
7. Clarke R, Daly L, Robinson K, Naughten E, Cahalane S, Fowler B, Graham I,: Hyperhomocysteinemia: An independent risk factor for vascular disease. N Engl J Med 1991: 324:1149-1155.
8. Amescn E, Refsum H, Bonaa KH, Uciand PM, Forde OH, Nordrehaug JE: Serum total homocysteine and coronary heart disease. Int J Epidemiol 1995:24:704-709.
9. Brattstrom LE. Lindgren A, Israels-son B. Malinow MR, Norrving B, Upson B. Hamfelt A: Hyperhomo-cystcinacmia in stroke: Prevalence, cause and relationships to type of stroke and stroke risk factors. Eur J Clin Invest 1992:22:214-221.
10. Genest JJ, McNamara JR. Salem DN. Wilson PWF, Schaefer EJ, Malinow MR: Plasma homocys-t(e)ine levels in men with premature coronary artery' disease. J Am Coll Cardiol 1990;16:1114-1119.
11. Israelsson B. Brattstrom LE. Hult-berg BL: Homocysteine and myocardial infarction. Atherosclerosis 1988:71:227-233.
12. Malinow MR. Sexton G. Averbuch M, Grosman M, Wilson D, Upson B: Homocyst(c)inemia in daily practice. Coron Artery Dis 1990:1:215-220.
13. Mölgaard J, Malinow MR, Lassvik C. Holm AC, Upsin B. Olsson AG: Hyperhomocyst(e)inemia. an independent risk factor for intermittent claudication. J Intern Med 1992; 231:273-279.
14. Pancharuniti N, Lewis CA, Säuberlich HE. Perkins LL, Go RCP. Alvarez JO, Macaluso M, Acton RT, Copeland RB. Cousins AL, Gore TB. Cornwell PE. Roseman JM: Plasma homocyst(e)ine, folate and vitamin B12 concentrations and risk for early-onset coronary artery disease. Am J Clin Nutr 1994:59:940-948.
15. Stampfer MJ. Malinow MR, Willett WC, Newcomer LM. Upson B. Ul-mann D. Tishler PV, Hennekens CH: A prospective study of plasma homocyst(e)ine and risk of myocardial infarction in US physicians. JAMA 1992;268:877-881.
16. Boushcy CJ, Beresford SA, Om-enn GS, Motulsky AG: A quantitative assessment of plasma homocysteine as a risk factor for vascular disease. JAMA 1995;274:1049-1057.
17. Coull BM, Malinow MR, Beamer N, Sexton G, Nordt F, Degarmo P,: Elevated plasma homocyst(e)ine concentration as a possible independent risk factor for stroke. Stroke 1990; 21:572-576.
18. Hopkins PN, Wu LL, Wu J, Hunt SC, James BC, Vincent GM, Williams RR,: Higher plasma homocys-t(e)ine and increased susceptibility to adverse effects of low folate in early familial coronary artery' disease. Artcrioscler Thromb Vase Biol 1995;15:1314-1320.
19. Graham IM, Daly LE, Refsum HM, Robinson K, Brattstrom LE, Ueland PM, Palma-Reis RJ, Boers GHJ, Sheahan RG, Israelsson B, Uiter-waal CS, Meleady R, McMaster D, Verhoef P, Witteman J, Rubba P, Bellet H, Wautrecht JC, de Valk HW, Sales Luis AC, Parrol-Roulaud FM, Tan KS. Higgins I, Garcon D, Medrano MJ, Candito M, Evans AE, Andria G,: Plasma homocysteine as a risk factor for vascular disease. The European Concerted Action Project. JAMA 1997;277: 1775-1781.
20. Dierkes J: Vitamin requirements for the reduction of homocysteine blood levels in healthy young women: PhD thesis. University of Bonn. 1994.
21. Miller KW, Nadeau MR, Sniith D. Selhub J: Vitamin B6 deficiency vs. folate deficiency: Comparison of responses to methionine loading in rats. Am J Clin Nutr 1994;59:1033-1039.
22. Jacobsen DW, Chen P, O’Keeffe, Poddar R, Kruger DW, Robinson K,: Homocysteine metabolism in human vascular cells and tissues. Pteridines 1997;8:157.
23. Deutsche Gesellschaft für Ernährung: Empfehlungen für die Nährstoffzufuhr. 5. Überarbeitung. Frankfurt am Main. Umschau. 1991.
24. Ubbink JB. Vermaak WJH, van der Merwc A, Becker PJ, Dclport R. Potgieter HC: Vitamin requirements for the treatment of hyperhomocysteinemia in humans. J Nutr 1994;124:1927-1933.
25. Brönstrup A, Pietrzik K: Bedeutung von Homocystein bei der Entstehung von Atherosklerose: Ist eine Supplementierung von Vitaminen sinnvoll? EU 1996:43:80-87.
26. Pietrzik K, Prinz-Langenohl R, Dierkes J,: Die Beeinflussung des Homocysteinspiegels durch nutritive Gaben der Vitamine Bu, Bi und Folsäure. Vitamin MinerSpur 1995: 10:150-154.
27. Dierkes J, Kroesen M, Pietrzik K,: Folic acid and vitamin B6 supplementation and plasma homocysteine concentrations in healthy young women. Int J Vitam Nutr Res 1997;67: in press.
28. Ward M. McNulty H. McPartlin J. Strain JJ. Weir DG. Scott JM: Plasma homocysteine, a risk factor for cardiovascular disease, is lowered by physiological doses of folic acid. QJ Med 1997;90:519-524.
29. Hages M, Pietrzik K: Untersuchungen zur Bewertung der Folatversor-gung bei Kindern unter Berücksichtigung des Cobalamin-und Eisenhaushalles. 1. Mitteilung: Veränderungen im Differentialblutbild in Abhängigkeit von den Vitamin-und Ferritinkonzentrationen in Serum bzw. Erythrozyten. Int.1 Vitam Nutr Res 1985:55:59-67.
30. Hages M, Pietrzik K: Untersuchungen zur Bewertung der Folatversor-gung bei Kindern unter Berücksichtigung des Cobalamin-und Eisenhaushalts. 2. Mitteilung: Häufigkeit und Schweregrad eines Folatman-gels. Int J Vitam Nutr Res 1985:55: 69-77.
31. Hages M, Pietrzik K, Rotthauwe HW, Weber HP, von Schnakenburg K,: Zur Folatversorgungssituation bei Kindern. Soz Pädiatr Prax Klin 1986;8:23-29.
32. Pietrzik K: Folate deficiency: Morphological and functional consequences; in Somogyi JC, Hejda S (ed): Nutrition in the Prevention of Disease. Bibl Nutr Dicta. Basel. Karger, 1989, vol 44. pp 123-130.
33. Pietrzik K: The Functional Significance of Marginal Micronutrient Status: Folate. Modem Life Styles, Lower Energy Intake and Micronutrient Status. Berlin, Springer. 1991, pp 103-114.
34. Bung P, Stein C. Bauer O. Schlebusch H, Krebs D, Prinz R. Pietrzik K: Folsäureversorgung in der Schwangerschaft: Ergebnisse einer prospektiven Longitudinalstudie. Geburtshilfe Fraucnheilkd 1993:53: 92-99.
35. Bung P, Bung C, Pietrzik K: Schwangerschaft und Ernährung: Risiko oder Selbstverständlichkeit. Perinat Med 1994:6:54-61.
36. Bung P. Pietrzik K: Einfluss der Vitaminversorgung auf Schwangcr-schaftsverlauf und fetale Entwicklung. Vitam Miner Spur 1995:10: 128-132.
37. Bung P, Prietl G, Willrodt A, Krebs D, Prinz-Langenohl R, Pietrzik K,: Idiopathische Infertilität und Sterilität: Spielt die Folsäure eine Schliis-sclrolle? J Fcrtil Reprod 1995:2:21-24.
38. Hages M, Jenkc M, Mirgel C. Pietrzik K: Bedeutung einer Folsäuresubstitution in der Schwangerschaft. Geburtshilfe Frauenheilkd 1989:6: 521-528.
39. Hages M. Thorand B. Prinz-Langenohl R. Bung P. Pietrzik K: Prävention von Neuralrohrdefekten (NRD) durch perikonzeptionelle Folsäuregaben: Eine Darstellung des aktuellen Forschungsstandes. Ge-burtsh Frauenheilk 1996:56:M59-M65.
40. Holzgreve W, Tercanli S, Pietrzik K,: Vitamins to prevent neural tube de-fees. Lancet 1991:338:639-640.
41. Pietrzik K. Prinz R, Bung P, Chro-nides A, Matlmann P, Reusch K: Folate status and pregnancy outcome. NY Acad Sei 1992:669:371-374.
42. Prinz R: Die Bewertung biochemischer Messgrössen in der Gravidität am Beispiel des Folat-und Eisenhaushalles und ihre Bedeutung für den Schwangcrschaftsvcrlauf: PhD thesis. University of Bonn, 1991.
43. Seller MJ, Nevin NC: Periconcep-tional vitamin supplementation and the prevention of neural tubedcfccts in South-East England and Northern Ireland. J Med Genet 1984:21: 325-330.
44. Stein C. Bung P, Prinz R, Pietrzik K: Do pregnant women need to take folic acid during pregnancy? Int J Gynecol Obstet 1991:1:39.
45. Thorand B. Hages M. Pietrzik K. Bung P. Holzgreve W: Homocysteine metabolism in pregnancy: Influence of folate and vitamin Bm status (abstract), Ir J Med Sei 1995; 164:20.
46. Mills L. McPartlin JM. Kirke PN. Lee YJ. Comley MR, Weir DG, Scott JM: Homocysteine metabolism in pregnancies complicated by neural-tube defects. Lancet 1995: 345:149-151.
47. Hibbard BM: The role of folic acid in pregnancy: With particular reference to anaemia, abruption and abortion. J Obstet Gynaecol Br Contmonw 1964;71:529-542.
48. Hibbard ED. Smithells RW: Folic acid metabolism and human embryopathy. Lancet 1965;1: 1254.
49. Smithells RW, Sheppard S, Schorah CJ,: Vitamin deficiencies and neural tube defects. Arch Dis Child 1976: 51:944-949.
50. Yates JRW, Ferguson-Smith MA, Guzman-Rodriques R, White M, Clark BJ,: Is disordered folate metabolism the basis for the genetic predisposition to neural tube defects? Clin Genet 1987;30:167-172.
51. Laurence KM, James N, Miller H, Tennand GB, Campbell FI: Doubleblind randomized controlled trial of folate treatment before conception to prevent recurrence of neural tube defects. Br Med J 1981:282:1509-1511.
52. Smithells RW, Nevin NC, Seller MJ, Sheppard S, Harris R, Read AP, Fielding DW, Waldcr S, Schorah CJ, Wild J: Further experience of vitamin supplementation for prevention of neural tube defect recurrences. Lancet 1983;1: 1027-1031.
53. Seller MJ, Nevin NC: Periconcep-tional vitamin supplementation and the prevention of neural tube defects in South-East-England and Northern Ireland. J Med Genet 1984:21: 325-330.
54. Mulinare J, Cordero JF, Erickson JD, Berry RJ,: Periconceptional use of multivitamins and the occurrence of neural tube defects. JAMA 1988: 260:3141-3145.
55. Milunsky A. Jick SS. Bruell CL, MacLaughlin DS. Rothntann KJ, Willett W: Multivitamin/folic acid supplementation in early pregnancy reduces the prevalence of neural tube defects. JAMA 1989:262: 2847-2852.
56. Bower C. Stanley RJ: Dietary' folate as a risk factor for neural tube defects: Evidence from a case-control study in Western Australia. Med J Aust 1989;150:613-619.
57. Mills JL. Rhoads GG. Simpson JL. Cunningham GC, Conley MR, Lass-man MR. Walden ME. Depp R. Hoffman HJ: The absence of a relation between the periconceplional use of vitamins and neural tube defects. N Engl J Med 1989:321:430-435.
58. Vergel RG, Sanchez LR, Heredcro BL,: Primary prevention of neural lube defects with folic acid supplementation: Cuban experience. Prc-nat Diagn 1990;10:149-152.
59. MRC Vitamin Study Research Group: Prevention of neural tube defects: Results of the Medical Research Council Vitamin Study. Lancet 1991:338:131-137.
60. Czeizcl AE, Dudas I: Prevention of the first occurrence of neural tube defects by periconccptional vitamin supplementation. N Engl.J Med 1992:327:1832-1835.
61. Werter MM. Shapiro S. Mitchell AA: Periconceptional folic acid exposure and risk of occurrent neural tube defects. JAMA 1993:269: 1257-1261.
62. Kries R, von Lenard HG,: Anmerkungen zur Prävention von Neuralrohrdefekten (NRD) durch Folsäure. Monatsschr Kindcrhcilkd 1994:142:705-711.
63. Stccgcrs-Thcunissen RPM. Smith-ells RW. Eskes TKAB: Update of new risk factors and prevention of neural-tube defects. Obstet Gynecol Surv 1993:48:287-293.
64. Steegers-Theunissen RPM, Boers GHJ, Trijbels FJM, Eskes TKAB,: Neural-tube defects and derangement of homocysteine metabolism. N Engl J Med 1991;324:199-200.
65. Molloy AM. Mills JL. Kirke PN. Ramsbottom D, McPartlin J, Daly S. Whitehead AS. Burke H. Conley M. Weir DG. Scott SM: The influence of 5,10-mcthylenctctrahy-drofolate reductase C677T genotypes on folate related risk factors of neural tube defects. Pteridincs 1997: 8:84-85.
66. Hages M, Thorand B, Dierkes J, Pietrzik K, Holzgrevc W,: Einfluss der mütterlichen FolatVersorgung auf den HomocystcinstofTWechsel in der Schwangerschaft. Z Ernährungs-wiss 1995:1:76.
67. James SJ, Yin L, Diet-induced DNA damage and altered nucleotide metabolism in lymphocytes front meth-yl-donor-defieient rats. Carcinogenesis 1989;10:1209-1214.
68. James SJ, Cross DR, Miller BJ,: Alterations in nucleotide pools in rats fed diets deficient in choline, methionine and/or folic acid. Carcinogenesis 1992:13:2471-2474.
69. Kunz BA: Mutagenesis and dcsoxy-ribonucleotide pool imbalance. Mu-tatRes 1988;200:133-147.
70. MacGregor JT. Schlegc R. Wehr CM. Alperin P. Ames BN: Cytogenetic damage induced by folate deficiency in mice is enhanced by caffeine. Proc Natl Acad Sei USA 1990; 87:9962-9965.
71. Eto I, Krumdieck CL: Role of vitamin B11 and folate deficiencies in carcinogenesis. Adv Exp Med Biol 1986:206:313-330.
72. Rogers AE,: Methyl donors in the diet and responses to chemical carcinogens. Am J Clin Nutr 1995; 61(suppl):659-665.
73. Rose DP, Boyar AP, Wynder EL. Internatinoal comparisons of mortality rates for cancer of the breast, ovary, prostate and colon, and per capita food consumption. Cancer 1986;58:2363-2371.
74. Food and Nutrition Board. National Research Council: Recommended Dietary Allowances, ed 10. Washington, National Academy Press. 1989, p 150.
75. Truswell AS: Prospects for folic acid fortification and its monitoring. Aust J Nutr Diet 1996:53:517-523.
76. Anonymous: Food Chemical News, March II 1996.
77. Kolctzko B. von Kries R: Prävention von Neuralrohrdefekten durch Folsäurezufuhr in der Frühschwangerschaft. Frauenarzt 1994: 35:1010-1107.
78. Editorial: A warning regarding the use of folic acid. N Engl J Med 1947; 237:711-714.
79. Schwartz SO. Kaplan SR. Armstrong BE: The longterm evaluation of folic acid in the treatment of pernicious anemia. J Lab Clin Med 1950:35:894-898.
80. Conley CL. Krevans JR: Development of neurological manifestations of pernicious anemia during multivitamin therapy. N Engl J Med 1951:245:529-531.
81. Editorial: Folic acid fortification. Nutr Rev 1996;54:94-95.
82. Chien I.T. Krumdieck CL. Scott CW. Butterworth CI,: Harmful effects of mcgadoscs of vitamins: Electroencephalogram abnormalities and seizures induced by intravenous folate in drug-treated epileptics. Am J Clin Nutr 1975;28:51-58.
83. Biale Y. Lewenthal H: Effects of folic acid supplementation on congenital malformations due to anti-convulsive drugs. Eur J Obstet Gynecol ReprBiol 1984;18:211-216.
84. Consensus Guidelines: Preconception counseling, management and care of the pregnant woman with epilepsy. Neurology 1992,42:149-160.
85. Dansky LV, Andermann E, Rosenblatt D. Sherwin AL, Andcrman F: Anticonvulsants, folate levels and pregnancy outcome: A prospective study. Ann Neurol 1987;27:176-182.
86. Kelly P. McPartlin J. Saggins M. Weir DG. Scott JM: Unmetabolized folic acid in serum: Acute studies in subjects consuming fortified food and supplements. Am J Clin Nutr 1997;65:1790-1795.
87. Mock B. Wcltermann B. Prinz-Lan-genohl R. Höpp HW. Pietrzik K: Stellenwert des Homocysteins im Präventionskonzept der koronaren Herzkrankheit. Herz Kreislauf 1997;29:213-218.